Synaffix wins ‘Best ADC Platform Technology’ at World ADC Awards

Published: 15-Sep-2022

This marks the second time that Synaffix’s ADC platform technology has been acknowledged as industry leading

Dutch biotechnology company Synaffix has won ‘Best ADC Platform Technology’ at the World ADC Awards Ceremony 2022.

The 2022 World ADC Awards finalists were shortlisted through a voting pool of over 2,500 individuals, with a panel of distinguished, independent world-renowned ADC experts assessing each finalist to decide the winners.

Synaffix' proprietary ADC technology platform consists of GlycoConnect, HydraSpace and toxSYN technologies. These technologies are aimed at enabling best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability.

Floris van Delft, Chief Scientific Officer of Synaffix, said: "We are thrilled to have won the 'Best ADC Technology Platform' Award again. This appreciation shown by our industry peers is testament to the creativity and skills of our scientific team that has developed our proprietary best-in-class ADC platform. It's fantastic to see that our technology is now being used to develop 18 different targeted cancer therapeutics across 10 collaborations with top-tier biotech and pharma companies, potentially leading to better cures for cancer patients. We would not be at this stage without our partners and are very grateful for their continued trust and support."

It's fantastic to see that our technology is now being used to develop 18 different targeted cancer therapeutics across 10 collaborations with top-tier biotech and pharma companies

Synaffix is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect, HydraSpace and toxSYN, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.

The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix' technology provide end-to-end protection of the manufacturing technology as well as the resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.

Trending Articles

You may also like